-
Basel, September 1, 2022 — Novartis today announced that James (Jay) E. Bradner, M.D., will step down from the Executive Committee of Novartis (ECN), effective October 31st after seven years leading research at Novartis. Fiona H. Marshall, Ph.D., currently Senior Vice President and Global Head of Discovery Sciences, Preclinical Development and…Women in ScienceDrug DiscoveryBiomedical Research
-
Drug DiscoveryNeurodegenerative DiseaseNeuroscienceNovartis Institutes for BioMedical ResearchScientific Research -
CancerDrug DiscoveryNovartis Institutes for BioMedical ResearchOncologyWomen in Science -
Novartis is collaborating with Microsoft to apply machine learning to medicinal chemistry — part of an effort to leverage AI to bring treatments to patients more efficiently.
Biomedical ResearchData ScienceDrug DevelopmentDrug DiscoveryEmerging Technology -
Inside the hunt for new antivirals to combat the current pandemic and to prepare for future ones.
Biomedical ResearchCOVID-19Drug DiscoveryNovartis Institutes for BioMedical ResearchScientific Research -
Basel, November 5, 2020 — Novartis, a leader in rheumatology and immuno-dermatology, today announced 12-week results from the first-of-its-kind Phase IIIb ULTIMATE randomized controlled trial, which demonstrated the significant treatment response of Cosentyx® (secukinumab) on synovitis (joint lining inflammation) in psoriatic arthritis (PsA)…Scientific ResearchInnovationDrug Discovery
-
Basel, November 6, 2020 — Novartis today announced new data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial evaluating the efficacy and safety of canakinumab in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)6. The ongoing trial failed to meet its primary endpoint…Scientific ResearchDrug Discovery
-
Basel, March 30, 2021 — Novartis announced today that the European Commission has approved Kesimpta® (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults with active disease defined by clinical or imaging features. Kesimpta is a targeted, precisely dosed and delivered B-cell therapy that has shown superior…NeuroscienceInnovationDrug Discovery
-
Basel, April 15, 2021 — Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient (API) for Roche’s Actemra/RoActemra® (tocilizumab), a treatment for rheumatoid arthritis which is also being tested in various clinical trials investigating…Reimagine MedicineFuture of HealthcareDrug Discovery
-
Basel, April 23, 2021 — Novartis today announced plans to initiate SMART, a Phase 3b clinical study to evaluate the safety and efficacy of Zolgensma® (onasemnogene abeparvovec) in young children with spinal muscular atrophy (SMA) weighing ≥ 8.5 kg and ≤ 21 kg, following a one-time, intravenous (IV) infusion. The new clinical data will supplement…Drug DiscoveryChildren's HealthCell and Gene Therapy
-
Basel, May 1, 2021 — Novartis today announced positive one-year results of the Phase III KESTREL and KITE* studies, evaluating the efficacy and safety of Beovu® (brolucizumab) 6 mg in diabetic macular edema (DME). Both studies met their primary endpoints of non-inferiority in change in best corrected visual acuity (BCVA) from baseline for Beovu 6…OphthalmologyEye CareDrug Discovery
-
Holzkirchen, May 3, 2021 – Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly1.OphthalmologyDrug DiscoveryBiomedical Research
-
-
-
Novartis is collaborating with Microsoft to apply machine learning to medicinal chemistry — part of an effort to leverage AI to bring treatments to patients more efficiently.
-
Inside the hunt for new antivirals to combat the current pandemic and to prepare for future ones.